Ken Griffin’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-20,400
| Closed | -$385K | – | 10216 |
|
|
2019
Q3 | $385K | Buy |
20,400
+10,400
| +104% | +$119K | ﹤0.01% | 7194 |
|
|
2019
Q2 | $118K | Buy |
+10,000
| New | +$121K | ﹤0.01% | 8479 |
|
|
2019
Q1 | – | Sell |
-43,500
| Closed | -$446K | – | 10212 |
|
|
2018
Q4 | $446K | Sell |
43,500
-6,800
| -14% | -$87.1K | ﹤0.01% | 6570 |
|
|
2018
Q3 | $837K | Buy |
50,300
+1,000
| +2% | +$18.1K | ﹤0.01% | 5845 |
|
|
2018
Q2 | $779K | Buy |
+49,300
| New | +$749K | ﹤0.01% | 5637 |
|
|
2018
Q1 | – | Sell |
-10,000
| Closed | -$115K | – | 9070 |
|
|
2017
Q4 | $115K | Sell |
10,000
-5,100
| -34% | -$56.9K | ﹤0.01% | 7386 |
|
|
2017
Q3 | $185K | Sell |
15,100
-10,300
| -41% | -$107K | ﹤0.01% | 6756 |
|
|
2017
Q2 | $291K | Buy |
+25,400
| New | +$470K | ﹤0.01% | 5964 |
|
|
2016
Q4 | – | Sell |
-15,800
| Closed | -$518K | – | 8155 |
|
|
2016
Q3 | $518K | Buy |
+15,800
| New | +$481K | ﹤0.01% | 4805 |
|
|
2016
Q2 | – | Sell |
-15,500
| Closed | -$380K | – | 7699 |
|
|
2016
Q1 | $380K | Buy |
15,500
+3,900
| +34% | +$90.3K | ﹤0.01% | 4790 |
|
|
2015
Q4 | $383K | Sell |
11,600
-2,400
| -17% | -$81.2K | ﹤0.01% | 4847 |
|
|
2015
Q3 | $459K | Buy |
14,000
+1,000
| +8% | +$42.5K | ﹤0.01% | 4920 |
|
|
2015
Q2 | $689K | Buy |
+13,000
| New | +$473K | ﹤0.01% | 4496 |
|
Ken Griffin's ALDR Position: Q4 2019 in Review
Ken Griffin sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 633,162 shares — an estimated $11.9M sold.
Ken Griffin first reported a position in ALDR in Q3 2014 and held it in 21 quarters. The position peaked at $42.3M in Q1 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Ken Griffin reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Ken Griffin sold 633,162 Alder Biopharmaceuticals shares in Q4 2019, an estimated $11.9M.
- Ken Griffin first reported a position in Alder Biopharmaceuticals in Q3 2014 and held it in 21 quarters.
- Ken Griffin's Alder Biopharmaceuticals position peaked at $42.3M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.